-
Mashup Score: 0ASH Clinical News: December 2024 From the Desk Of... - 27 day(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews what’s to come in the December issue. Highlights include a feature article examining the Netflix …
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Experts Release Guidance on Liver-Related Toxicities With Gene Therapy for Hemophilia A | ASH Clinical News | American Society of Hematology - 29 day(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Patients with hemophilia A who have received valoctocogene roxaparvovec gene therapy need to be managed carefully to minimize their risk of hepatotoxicity, according to new guidelines published in Blood Advances. The authors, an interdisciplinary group of 13 hepatology and hemophilia experts, suggest that a pretreatment assessment and ongoing monitoring of liver health after gene therapy administration may prevent
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Published in @BloodAdvances, new guidelines on liver-related complications in patients with #hemophiliaA who have received valoctocogene roxaparvovec #genetherapy emphasize pretreatment assessments and ongoing #liver monitoring post-therapy: https://t.co/Zls5NGzPJs
-
-
Mashup Score: 0
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. A large, single-center analysis of pediatric patients with either acquired aplastic anemia (aAA) or immune thrombocytopenia (ITP) has compared the serum thrombopoietin (TPO) levels in these patients. The results, from more than 400 patients, show that serum TPO levels were elevated in those pediatric patients diagnosed with aAA compared to ITP. In patients with aAA, serum TPO levels were highest in very severe AA.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
A large, single-center analysis of #pediatric patients with either acquired #AplasticAnemia (aAA) or #ImmuneThrombocytopenia compared the serum TPO levels in these patients and found that serum levels were higher in patients with aAA: https://t.co/WvItagyGZp
-
-
Mashup Score: 4
Mid-November 2024 | ASH Clinical News | American Society of Hematology Mid-November 2024 Developments and Discoveries With advances in hematology emerging daily, the 2024 ASH Annual Meeting and Exposition offers hematologists the chance to stay on the cutting edge.  Viewpoints Editor’s Corner Peer Review and the Yellow Brick Road Education Hematologica Obscura Hematologists Should Consider Sitosterolemia in Patients with Hemolytic…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
See what's to come at #ASH24 in this month's bonus issue! Special highlights include interviews with the Education and Scientific program co-chairs and previews of sessions on #aging, #endoflife care, and treatment of smoldering #myeloma 🩸 https://t.co/hxop5ClUpB https://t.co/fyUjTqxTps
-
-
Mashup Score: 0
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. An analysis of treatment-naïve patients with acute myeloid leukemia (AML) receiving venetoclax plus azacitidine demonstrates that the European LeukemiaNet (ELN) AML genetic risk classification systems do not provide clinically meaningful stratification of overall survival (OS) for patients who are ineligible for intensive chemotherapy. The authors of the study, which was published in Blood, also provide a four-gene
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
A new genetics-based risk model aims to predict survival outcomes for patients with #AML treated with #venetoclax and #azacitidine. By analyzing genetic mutations, the model may stratify OS outcomes more accurately than the ELN risk classifications: https://t.co/JsJI4EXdgr
-
-
Mashup Score: 1Early Aggressive Treatment of High-Risk Smoldering MM Results in High Rates of Sustained uMRD | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Currently, the standard of care for the management of smoldering multiple myeloma (SMM) is observation. However, ear ly treatment of patients with high-risk (HR) SMM resulted in high rates of sustained undetectable measurable residual disease (uMRD) at the end of treatment, according to a trial published in the Journal of Clinical Oncology. 1 “The role of early treatment in SMM is a topic of ongoing debate. While research is still in
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Early, aggressive treatment of high-risk #SmolderingMultipleMyeloma led to high rates of sustained uMRD, according to recent research. This early intervention could delay progression, challenging the traditional "watch and wait" approach: https://t.co/OUwkMEEwGx https://t.co/Go4QGfB5Dw
-
-
Mashup Score: 0You Make the Call: How would you treat a patient with a history of bilateral PE and subsequent DVT? | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Kenneth A. Bauer, MD Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School A 39-year-old female has a history of bilateral pulmonary embolism (PE) after taking oral contraceptive pills (OCPs), as well as a subsequent deep vein thrombosis (DVT) in the left calf after a long car ride. Given the recurrent event and her history of venous thromboembolism (VTE), would you treat with indefinite anticoagulation? For both provoked and unprovoked below-the-knee DVT, I typically treat
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Check out what our expert had to say in this month's edition of You Make the Call! https://t.co/dOoDcPUoqm
-
-
Mashup Score: 2FDA Approves Hemophilia A, B Treatment | ASH Clinical News | American Society of Hematology - 1 month(s) ago
Marstacimab-hncq was approved by the U.S. Food and Drug Administration (FDA) as a prophylactic treatment for bleeding episodes in patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. The treatment is an anti-tissue factor pathway inhibitor that works by reducing the amount of anticoagulation protein and increasing the amount of thrombin. It is a subcutaneous, once-weekly treatment. Approval was granted based on the results of an open-label,
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Marstacimab-hncq was approved by the #FDA as prophylaxis for #bleeding episodes in patients with #hemophilia A and B after studies demonstrated it significantly reduced annualized bleeding rates compared with routine prophylaxis and on-demand treatment: https://t.co/3DSvqvCsT6
-
-
Mashup Score: 0Bluebird Bio Medication Linked to Blood Cancers | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Seven of 67 pediatric patients receiving Bluebird Bio’s elivaldogene autotemcel (eli-cel) for the treatment of cerebral adrenoleukodystrophy developed a blood cancer, according to a study published in the New England Journal of Medicine (NEJM). Of the patients who developed a hematologic malignancy, six were diagnosed with myelodysplastic syndromes (MDS) and one with acute myeloid leukemia (AML). These hematologic malignancies occurred at 14, 2 6, 28, 36, 42, 57, and 92 months after receiving eli-cel
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Seven out of 67 #pediatric patients who were receiving elivaldogene autotemcel for the treatment of #cerebral #adrenoleukodystrophy were reported to have developed a #blood #cancer, with diagnoses ranging from 14 to 92 months after treatment: https://t.co/Ioh0CqZPTU
-
-
Mashup Score: 3November 2024 | ASH Clinical News | American Society of Hematology - 2 month(s) ago
November 2024 | ASH Clinical News | American Society of Hematology November 2024 When Treatment Includes Substance Use Disorders A patient’s substance use disorder can complicate treatment for a hematologic condition, but physicians must view the comorbidity as an opportunity to provide support.  Viewpoints Editor’s Corner Bridging the Divide: Global Equity in CAR T-Cell Therapy Education You Make the Call…
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
The November issue is available now! Highlights include a feature on treating substance use disorders in patients with #hematologic diseases, findings on #ischemic #stroke rates in individuals with #SCD, and more. View the full issue here: https://t.co/3vxiEffAQ8 https://t.co/zoqkcmTmu9
-
Preview the December issue with @AaronGerds 🩸 Issue highlights include a feature article on #Netflix's #Supacell and portrayals of #sicklecelldisease in the media, a celebration of our 10-year anniversary, recent findings from @BloodJournal, and more! https://t.co/EJx9MdiyD0